Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients

Table 1 Study participant characteristics

	Healthy controls (n = 8)	Non-Jo-1 IIM* (n = 4)	Stable Jo-1+ disease** (n = 5)	Active Jo-1 disease*** (n = 5)
Age (years)	48.2 (42.1–52.0)	58.2 (50.9–63.2)	57.1 (43.4–57.4)	53.8 (46.2–56.1)
Sex (female)	5 (63)	3 (75)	5 (100)	3 (60)
Race
Caucasian	6 (75)	4 (100)	5 (100)	3 (60)
African American	1 (13)	0	0	2 (40)
Other ethnicity	1 (13)	0	0	0
Disease duration (years)	–	2 (0.5–2.7)	13.8 (4.6–14.5)	1.0 (0.8–4.0)
Daily steroid dose ≥ 20 mg	–	3 (75)	0	4 (80)
Other immunosuppressant use	–	2 (50)^†	5 (100)^‡	1 (20)^§

Data are presented as medians (interquartile ranges) and counts (percentages) for continuous and categorical data, respectively
*Anti-PL-7, anti-EJ with anti-Ro52, anti-Mi-2, and anti-TIF1-γ
**Stable Jo-1+ anti-synthetase syndrome defined as having no medication changes discussed, and current medications either continued or de-escalated at the time of blood draw
***Active Jo-1+ anti-synthetase syndrome defined as either immunosuppression increased during outpatient visit, or patient hospitalized with life-threatening disease at the time of blood draw
^†IVIG (1), methotrexate (1)
^‡Azathioprine (3), hydroxychloroquine (1), leflunomide (1)
^§IVIG (1)

ISSN: 1478-6362